Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808815 | 1.00 | OPRD1 (0.36) | OPRD1MGLLSNCALPLLIPG | |
| SCHEMBL28578224 | 0.84 | OPRD1 (0.35) | OPRD1LPLLIPG | |
| SCHEMBL16426133 | 0.84 | SNCA (0.38) | SNCALPLLIPG | |
| SCHEMBL5892498 | 0.78 | ALDH1A1 (0.36) | SNCALPLLIPG | |
| SCHEMBL5892480 | 0.78 | ACHE (0.36) | SNCALPLLIPG | |
| SCHEMBL16674036 | 0.78 | ACHE (0.38) | MGLLSNCALPLLIPG | |
| SCHEMBL3188699 | 0.77 | ALDH1A1 (0.37) | OPRD1SNCALPLLIPG | |
| SCHEMBL5892466 | 0.77 | MEN1 (0.38) | SNCALPLLIPG | |
| SCHEMBL1712145 | 0.77 | CYP3A4 (0.37) | SNCALPLLIPG | |
| SCHEMBL2274567 | 0.75 | LPL (0.42) | SNCALPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-12-09 | — | — | US | disclosed |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-03-07 | — | — | US | disclosed |
| EP-4046991-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2022-08-24 | — | — | EP | disclosed |
| US-20210024486-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20210024486-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| EP-3339296-A1 | HYDROXYTRIAZINE COMPOUND AND MEDICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20170057943-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-03-02 | — | — | US | disclosed |
| US-20170057943-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-03-02 | — | — | US | disclosed |
| US-20170057943-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024486-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | OPRD1 2287/4885MGLL 2064/4885SNCA 2150/4885 |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | OPRD1 2287/4885MGLL 2064/4885SNCA 2150/4885 |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | PTGS1, PTGIS, PTGES | OPRD1 2287/4885MGLL 2064/4885SNCA 2150/4885 |
| US-20170057943-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | OPRD1 2287/4885MGLL 2064/4885SNCA 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.